Bengaluru-based precision oncology startup 4baseCare has successfully closed its Series B funding round, raising a total of Rs 128 crore. The recent infusion of Rs 38 crore in fresh capital was led by growX Ventures, with participation from existing investors. This development is significant as it underscores the growing interest in healthcare technology solutions that address global disparities in cancer treatment.
### The Company and Its Innovations
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare is dedicated to revolutionizing precision oncology by addressing the lack of genomic data diversity, particularly for non-Western populations. The company is expanding its genomics laboratory network across India and internationally, including the Middle East, Southeast Asia, Latin America, and Central Asia. This expansion aims to improve access to advanced genomic testing and precision cancer care.
Central to 4baseCare’s offerings is its AI-powered platform, OncoTwin, which supports oncologists by providing clinically actionable insights derived from real-world clinico-genomic and outcomes-linked datasets. This capability enhances clinical decision-making and facilitates personalized cancer treatment for diverse populations.
### Context and Funding Environment
The successful Series B round, which initially raised Rs 90 crore in January with co-leads Ashish Kacholia and Lashit Sanghvi, is indicative of the robust interest in health tech within India’s startup ecosystem. The participation of growX Ventures, a B2B-focused venture capital firm with a diverse portfolio that includes sectors such as big data, AI, and genomics, highlights the strategic focus on addressing underrepresented segments in healthcare.
The Indian startup ecosystem has been witnessing a surge in health tech innovations, driven by the urgent need for scalable solutions in genomics and precision medicine. 4baseCare’s focus on underrepresented genomic data aligns with broader trends where investors are increasingly looking at startups that offer solutions with global applicability and significant impact potential.
### Implications for India’s Startup Ecosystem
4baseCare’s funding success is a testament to the potential of Indian startups to contribute to global healthcare challenges. By tackling the issue of genomic data diversity, 4baseCare not only advances cancer care but also positions itself as a leader in the precision oncology space. This positioning could catalyze further investments in similar startups that aim to bridge gaps in healthcare through technology.
The growth of health tech startups like 4baseCare is crucial for India, as it underscores the country’s ability to innovate and lead in sectors that require high-tech solutions. The focus on expanding to international markets also reflects the confidence in Indian innovations to meet global standards and needs.
Looking ahead, the next steps for 4baseCare involve accelerating its global expansion and further strengthening its AI-driven clinical decision support capabilities. For founders and investors, this sets a precedent in the health tech space — one where addressing niche but impactful problems can attract significant funding and facilitate global growth. Watching how 4baseCare navigates its international expansion and scales its technological solutions will be key for those looking to replicate its success.
